Emphasis on these specific preclinical studies will allow for an improved understand of the complex mechanistic interplay that exists between PD-1/PD-L1 inhibitors and other therapeutic agents, and the ultimate impact this exerts on the TME and diverse cancer signaling pathways. Here, CD274 is linked to cancer.